Novanta Inc. NOVT
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Existing position may be maintained at current valuation.
Strong order intake, earnings beat and raised full-year guidance are balanced by integration risks and moderate organic growth.
The market reacts positively to the strong organic growth and the raised outlook following the Riverpoint acquisition.
HOLD is the call. Positive is the market mood. Low risk means less can go wrong.
Latest change
- 10 Nov 2026 — The report shows strong organic growth and earnings beat that drive positive market view following the acquisition.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (3) — follow the company freeAbout the company
Novanta supplies precision components and subsystems to OEM customers in medical technology, robotics and advanced industry. The company operates three segments: Precision Medicine & Manufacturing, Medical Solutions and Robotics & Automation. Operations are profitable with growth both organically and through acquisitions.
Bull case
Accelerating organic growth and immediate positive contribution from the Riverpoint acquisition strengthen recurring revenues.
Bear case
High valuation requires continued perfection and integration risks could affect margins.
Why this signal
Strong order intake, earnings beat and raised full-year guidance are balanced by integration risks and moderate organic growth.
Recent news
Novanta released Q3 2026 results on November 9 with GAAP revenue of USD 305 M (+23 % YoY), adjusted EBITDA of USD 80.3 M (+38 %) and adjusted EPS of USD 1.05 (+21 %). The company beat estimates and raised full-year 2026 guidance. Shares rose 8 % to approximately USD 146 on the report day.